Tau protein in cerebrospinal fluid:: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis

被引:38
作者
Martínez-Yélamos, A
Saiz, A
Bas, J
Hernandez, JJ
Graus, F
Arbizu, T
机构
[1] Hosp Viladecans, Dept Neurol, Barcelona 08840, Spain
[2] Hosp Clin Barcelona, IDIBAPS, Neurol Serv, Barcelona 08036, Spain
[3] Hosp Duran & Reynals, Serv Immunol, Barcelona 08907, Spain
[4] Hosp Univ Bellvitge, Serv Neurol, Barcelona 08907, Spain
[5] Hosp Univ Bellvitge, Serv Neurol, Multiple Sclerosis Unit, Barcelona, Spain
关键词
Tau protein; cerebrospinal fluid; multiple sclerosis; axonal damage; disability; biochemical marker;
D O I
10.1016/j.neulet.2004.03.039
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We analyzed the prognostic value of Tau protein, a marker of axonal damage, detected in the cerebrospinal fluid (CSF) of patients with relapsing-remitting multiple sclerosis (RRMS). We sampled the CSF from 32 patients with probable or definite RRMS, having had the disease for less than 5 years. We studied the relationship between Tau protein concentration in the CSF (CSF-TAU) and disability, time to next relapse and time to experience a one point increase on the Expanded Disability Status Scale (EDSS). CSF-TAU was correlated with the Progression Index at the end of follow-up. Patients with higher CSF-TAU experienced a more rapid one point increase in the EDSS. CSF-TAU was the only independent variable to predict the time to next relapse. CSF-TAU, as a marker of axonal loss, may help us to predict short-term outcome in patients with early RRMS. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:14 / 17
页数:4
相关论文
共 10 条
[1]  
BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371
[2]   EDMUS, A EUROPEAN DATABASE FOR MULTIPLE-SCLEROSIS [J].
CONFAVREUX, C ;
COMPSTON, DAS ;
HOMMES, OR ;
MCDONALD, WI ;
THOMPSON, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (08) :671-676
[3]   Multiple sclerosis - Neurofilament light chain antibodies are correlated to cerebral atrophy [J].
Eikelenboom, MJ ;
Petzold, A ;
Lazeron, RHC ;
Silber, E ;
Sharief, M ;
Thompson, EJ ;
Barkhof, F ;
Giovannoni, G ;
Polman, CH ;
Uitdehaag, BMJ .
NEUROLOGY, 2003, 60 (02) :219-223
[4]   Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis [J].
Jiménez-Jiménez, FJ ;
Zurdo, JM ;
Hernanz, A ;
Medina-Acebrón, S ;
de Bostus, F ;
Barcenilla, B ;
Sayed, Y ;
Ayuso-Peralta, L .
ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (06) :351-354
[5]   Increased cerebrospinal fluid tau protein in multiple sclerosis [J].
Kapaki, E ;
Paraskevas, GP ;
Michalopoulou, M ;
Kilidireas, K .
EUROPEAN NEUROLOGY, 2000, 43 (04) :228-232
[6]   14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis [J].
Martínez-Yélamos, A ;
Saiz, A ;
Sanchez-Valle, R ;
Casado, V ;
Ramón, JM ;
Graus, F ;
Arbizu, T .
NEUROLOGY, 2001, 57 (04) :722-724
[7]   Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease [J].
Otto, M ;
Wiltfang, J ;
Cepek, L ;
Neumann, M ;
Mollenhauer, B ;
Steinacker, P ;
Ciesielezyk, B ;
Schulz-Schaeffer, W ;
Kretzschmar, HA ;
Poser, S .
NEUROLOGY, 2002, 58 (02) :192-197
[8]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231
[9]   Tau protein in cerebrospinal fluid (CSF):: a blood-CSF barrier related evaluation in patients with various neurological diseases [J].
Süssmuth, SD ;
Reiber, H ;
Tumani, H .
NEUROSCIENCE LETTERS, 2001, 300 (02) :95-98
[10]   Axonal transection in the lesions of multiple sclerosis [J].
Trapp, BD ;
Peterson, J ;
Ransohoff, RM ;
Rudick, R ;
Mörk, S ;
Bö, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :278-285